Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 355,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "fd853227-3176-43e4-96de-b68a5d589b69",
"title": "Global Hepatitis C Testing Market Is Expected to Reach $2.3 Billion by 2031: Says AMR",
"description": "Increase in blood transfusion and blood donation activities across the world drives the growth of the global hepatitis C testing market. Based on test, the...",
"keywords": "Allied Market Research, Hepatitis C Testing Market, Antibody test, Immunoassay, PCR, diagnostic laboratory, Genotype tests, Blood banks",
"snippet": "Portland, OR, Oct. 03, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Hepatitis C Testing Market siz...",
"url": "https://www.globenewswire.com/news-release/2022/10/03/2526511/0/en/Global-Hepatitis-C-Testing-Market-Is-Expected-to-Reach-2-3-Billion-by-2031-Says-AMR.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660?size=1",
"language": "en",
"published_at": "2022-10-03T07:22:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "BUWA.DE",
"name": "Bio-Rad Laboratories, Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.932638,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The key market players analyzed in the global hepatitis C testing market report include <em>BIO</em>-<em>RAD</em> <em>laboratories</em> <em>Inc</em>, Cosara Diagnostics Pvt Ltd, Meril Life Sciences Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., PerkinElmer, Qiagen N.V., Abbott Laboratories, Thermo Fisher Scientific Inc, Trivitron Healthcare, and Illumina Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b2cce622-d5b8-4c07-9b47-ca38064e447c",
"title": "CorMedix (NYSE:CRMD) Lifted to “Sell” at StockNews.com",
"description": "Read CorMedix (NYSE:CRMD) Lifted to “Sell” at StockNews.com at ETF Daily News",
"keywords": "CorMedix, NYSE:CRMD, CRMD, Health Technology, Upgrade, StockNews.com",
"snippet": "StockNews.com upgraded shares of CorMedix (NYSE:CRMD – Get Rating) to a sell rating in a report published on Friday morning.\n\nCorMedix Price Performance\n\nCRMD...",
"url": "https://www.etfdailynews.com/2022/10/03/cormedix-nysecrmd-lifted-to-sell-at-stocknews-com/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/upgrade-image.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T07:06:43.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "CRMD",
"name": "CorMedix Inc.",
"exchange": "NYSEAMERICAN",
"exchange_long": "NYSE American",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 69.93306,
"sentiment_score": 0.1606,
"highlights": [
{
"highlight": "StockNews.com upgraded shares of <em>CorMedix</em> (NYSE:CRMD – Get Rating) to a sell rating in a report published on Friday morning.\n\n<em>CorMedix</em> Price Performance\n\nCRMD opened at $2.83 on Friday. <em>CorMedix</em> has a 52 week low of $2.64 and a 52 week high of $8.02.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>CorMedix</em> alerts:\n\nAbout <em>CorMedix</em>\n\n(Get Rating)\n\nFeatured Stories\n\n<em>CorMedix</em>, <em>Inc</em> operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Receive News & Ratings for <em>CorMedix</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>CorMedix</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CorMedix</em> (NYSE:CRMD) Lifted to “Sell” at StockNews.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "756bf10b-fa12-49e6-aba6-04aadd024852",
"title": "Novo Nordisk A/S : Une opportunit?oyen terme ?",
"description": "Techniquement le timing apparaît pertinent dans une optique à moyen terme pour se positionner sur le titre Novo Nordisk A/S. La zone support des 735 DKK limite en effet le risque de baisse et devrait... | 3 octobre 2022",
"keywords": "NOVO NORDISK A/S bourse, information, actualité, communiqué de presse, news, techniquement, timing, apparaît, pertinent, optique, moyen, terme, se, positionner, titre, novo, nordisk, zone, support, 735, dkk, limite, effet, risque, baisse | NOVO B | DK0060534915",
"snippet": "Novo Nordisk A/S : Une opportunité moyen terme ? 03/10/2022 | 08:37 achat En attente\n\nCours d'entrée : 761.4DKK | Objectif : 820DKK | Stop : 730DKK | Potentie...",
"url": "https://www.zonebourse.com/cours/action/NOVO-NORDISK-A-S-1412980/actualite-bourse/Une-opportunite-moyen-terme--41911349/",
"image_url": "https://www.zonebourse.com/graf/as41911349.gif",
"language": "fr",
"published_at": "2022-10-03T06:37:57.000000Z",
"source": "zonebourse.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.477157,
"sentiment_score": null,
"highlights": [
{
"highlight": "., INC. 12.37% 218 166 <em>ASTRAZENECA</em> <em>PLC</em> 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573\n\n© Zonebourse.com 2022 Avertissement : Les informations, graphiques, chiffres, opinions ou commentaires mis à disposition par SURPERFORMANCE SAS s'adressent à des investisseurs disposant des connaissances",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4AB.DE",
"name": "AbbVie Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.715565,
"sentiment_score": null,
"highlights": [
{
"highlight": ". -25.89% 245 597 <em>ABBVIE</em> <em>INC</em>. -0.88% 237 296 MERCK & CO., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573\n\n© Zonebourse.com 2022 Avertissement : Les informations, graphiques, chiffres, opinions ou commentaires mis à disposition par SURPERFORMANCE SAS",
"sentiment": -0.128,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.DE",
"name": "Pfizer Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.301177,
"sentiment_score": null,
"highlights": [
{
"highlight": "NOVO NORDISK A/S 3.59% 227 057 JOHNSON & JOHNSON -4.51% 429 503 ELI LILLY AND COMPANY 17.06% 307 239 ROCHE HOLDING AG -14.68% 271 055 <em>PFIZER</em>, <em>INC</em>. -25.89% 245 597 ABBVIE INC. -0.88% 237 296 MERCK & CO., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVC.DE",
"name": "Novo Nordisk A/S",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 179.68137,
"sentiment_score": null,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> : Une opportunité moyen terme ? 03/10/2022 | 08:37 achat En attente\n\nCours d'entrée : 761.4DKK | Objectif : 820DKK | Stop : 730DKK | Potentiel : 7.7% Techniquement le timing apparaît pertinent dans une optique à moyen terme pour se positionner sur le titre <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>NOVO</em> <em>NORDISK</em> <em>A</em>/<em>S</em> 3.59% 227 057 JOHNSON & JOHNSON -4.51% 429 503 ELI LILLY AND COMPANY 17.06% 307 239 ROCHE HOLDING AG -14.68% 271 055 PFIZER, INC. -25.89% 245 597 ABBVIE INC. -0.88% 237 296 MERCK & CO., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Données financières DKK USD EUR CA 2022 171 Mrd 22 581 M 23 029 M Résultat net 2022 54 527 M 7 185 M 7 327 M Tréso. nette 2022 1 098 M 145 M 148 M PER 2022 31,3x Rendement 2022 1,53% Capitalisation 1 723 Mrd 227 Mrd 232 Mrd VE / CA 2022 10,0x VE / CA 2023 8,77x Nbr Employés 50 816 Flottant 69,6% Prochain événement sur <em>NOVO</em> <em>NORDISK</em> <em>A</em>/<em>S</em> 02/11/22 Q3 2022",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> : Une opportunit?oyen terme ?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.786572,
"sentiment_score": null,
"highlights": [
{
"highlight": ". -0.88% 237 296 <em>MERCK</em> & <em>CO</em>., <em>INC</em>. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573\n\n© Zonebourse.com 2022 Avertissement : Les informations, graphiques, chiffres, opinions ou commentaires mis à disposition par SURPERFORMANCE SAS s'adressent à des investisseurs",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 28.411634,
"sentiment_score": null,
"highlights": [
{
"highlight": "NOVO NORDISK A/S 3.59% 227 057 JOHNSON & JOHNSON -4.51% 429 503 <em>ELI</em> <em>LILLY</em> <em>AND</em> <em>COMPANY</em> 17.06% 307 239 ROCHE HOLDING AG -14.68% 271 055 PFIZER, INC. -25.89% 245 597 ABBVIE INC. -0.88% 237 296 MERCK & CO., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 179.66774,
"sentiment_score": null,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> : Une opportunité moyen terme ? 03/10/2022 | 08:37 achat En attente\n\nCours d'entrée : 761.4DKK | Objectif : 820DKK | Stop : 730DKK | Potentiel : 7.7% Techniquement le timing apparaît pertinent dans une optique à moyen terme pour se positionner sur le titre <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>NOVO</em> <em>NORDISK</em> <em>A</em>/<em>S</em> 3.59% 227 057 JOHNSON & JOHNSON -4.51% 429 503 ELI LILLY AND COMPANY 17.06% 307 239 ROCHE HOLDING AG -14.68% 271 055 PFIZER, INC. -25.89% 245 597 ABBVIE INC. -0.88% 237 296 MERCK & CO., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Données financières DKK USD EUR CA 2022 171 Mrd 22 581 M 23 029 M Résultat net 2022 54 527 M 7 185 M 7 327 M Tréso. nette 2022 1 098 M 145 M 148 M PER 2022 31,3x Rendement 2022 1,53% Capitalisation 1 723 Mrd 227 Mrd 232 Mrd VE / CA 2022 10,0x VE / CA 2023 8,77x Nbr Employés 50 816 Flottant 69,6% Prochain événement sur <em>NOVO</em> <em>NORDISK</em> <em>A</em>/<em>S</em> 02/11/22 Q3 2022",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> : Une opportunit?oyen terme ?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "AMG.DE",
"name": "Amgen Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.97203,
"sentiment_score": null,
"highlights": [
{
"highlight": "., INC. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 <em>AMGEN</em> <em>INC</em>. 0.19% 120 573\n\n© Zonebourse.com 2022 Avertissement : Les informations, graphiques, chiffres, opinions ou commentaires mis à disposition par SURPERFORMANCE SAS s'adressent à des investisseurs disposant des connaissances",
"sentiment": 0.3818,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.PA",
"name": "Merck & Co., Inc.",
"exchange": "EPA",
"exchange_long": "Euronext Paris",
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.786411,
"sentiment_score": null,
"highlights": [
{
"highlight": ". -0.88% 237 296 <em>MERCK</em> & <em>CO</em>., <em>INC</em>. 12.37% 218 166 ASTRAZENECA PLC 14.59% 171 692 NOVARTIS AG -5.92% 167 984 BRISTOL-MYERS SQUIBB COMPAN.. 14.02% 151 795 AMGEN INC. 0.19% 120 573\n\n© Zonebourse.com 2022 Avertissement : Les informations, graphiques, chiffres, opinions ou commentaires mis à disposition par SURPERFORMANCE SAS s'adressent à des investisseurs",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "20e9afa0-1a2e-4778-aea1-c7904319bfbb",
"title": "Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Decline in Short Interest",
"description": "Read Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Decline in Short Interest at ETF Daily News",
"keywords": "Kodiak Sciences, NASDAQ:KOD, KOD, Medical, Stocks, Options, Put, Call",
"snippet": "Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) was the target of a significant decrease in short interest during the month of September. As of September 15th,...",
"url": "https://www.etfdailynews.com/2022/10/03/kodiak-sciences-inc-nasdaqkod-sees-significant-decline-in-short-interest/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/kodiak-sciences-inc-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:32:52.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "KOD",
"name": "Kodiak Sciences Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 198.7526,
"sentiment_score": 0.529027,
"highlights": [
{
"highlight": "<em>Kodiak</em> <em>Sciences</em> <em>Inc</em>. (<em>NASDAQ:KOD</em> – Get Rating) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 3,590,000 shares, a decrease of 5.0% from the August 31st total of 3,780,000 shares. Currently, 7.3% of the shares of the stock are sold short.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kodiak</em> <em>Sciences</em> Price Performance\n\nShares of <em>Kodiak</em> <em>Sciences</em> stock opened at $7.74 on Monday. <em>Kodiak</em> <em>Sciences</em> has a fifty-two week low of $4.90 and a fifty-two week high of $26.39. The firm has a fifty day moving average price of $9.90 and a two-hundred day moving average price of $8.35.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>Kodiak</em> <em>Sciences</em> alerts:\n\n<em>Kodiak</em> <em>Sciences</em> (<em>NASDAQ:KOD</em> – Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($1.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.77) by $0.03. During the same quarter in the prior year, the company earned ($1.08) EPS.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Analysts expect that <em>Kodiak</em> <em>Sciences</em> will post -7.12 earnings per share for the current fiscal year.\n\nInstitutional Investors Weigh In On <em>Kodiak</em> <em>Sciences</em>\n\nAnalyst Ratings Changes\n\nSeveral hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Ltd. bought a new position in <em>Kodiak</em> <em>Sciences</em> in the second quarter valued at approximately $84,000. Tiedemann Advisors LLC bought a new stake in shares of <em>Kodiak</em> <em>Sciences</em> in the first quarter worth $92,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of <em>Kodiak</em> <em>Sciences</em> in the first quarter worth $101,000.",
"sentiment": 0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Martingale Asset Management L P bought a new stake in shares of <em>Kodiak</em> <em>Sciences</em> in the second quarter worth $103,000. Finally, Bridgefront Capital LLC bought a new stake in shares of <em>Kodiak</em> <em>Sciences</em> in the first quarter worth $103,000. Institutional investors and hedge funds own 78.37% of the company’s stock.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Chardan Capital dropped their price objective on shares of <em>Kodiak</em> <em>Sciences</em> from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Citigroup lowered shares of <em>Kodiak</em> <em>Sciences</em> from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 2nd.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "The Goldman Sachs Group increased their price target on shares of <em>Kodiak</em> <em>Sciences</em> to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 9th.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "According to data from MarketBeat, <em>Kodiak</em> <em>Sciences</em> currently has a consensus rating of “Hold” and an average target price of $36.22.\n\n<em>Kodiak</em> <em>Sciences</em> Company Profile\n\n(Get Rating)\n\n<em>Kodiak</em> <em>Sciences</em> <em>Inc</em>, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Recommended Stories\n\nReceive News & Ratings for <em>Kodiak</em> <em>Sciences</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Kodiak</em> <em>Sciences</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.7034,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kodiak</em> <em>Sciences</em> <em>Inc</em>. (<em>NASDAQ:KOD</em>) Sees Significant Decline in Short Interest",
"sentiment": 0.5859,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "bbe3f79c-ab25-479a-a4f2-dbfd77cd9a6e",
"title": "ATI Physical Therapy, Inc. (NYSE:ATIP) Sees Large Decline in Short Interest",
"description": "Read ATI Physical Therapy, Inc. (NYSE:ATIP) Sees Large Decline in Short Interest at ETF Daily News",
"keywords": "ATI Physical Therapy, NYSE:ATIP, ATIP, Medical, Stocks, Options, Put, Call",
"snippet": "ATI Physical Therapy, Inc. (NYSE:ATIP – Get Rating) saw a large decline in short interest in September. As of September 15th, there was short interest totalli...",
"url": "https://www.etfdailynews.com/2022/10/03/ati-physical-therapy-inc-nyseatip-sees-large-decline-in-short-interest/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/generic-stocks.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T05:58:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 21.880127,
"sentiment_score": 0.743,
"highlights": [
{
"highlight": "Finally, <em>BlackRock</em> <em>Inc</em>. lifted its holdings in ATI Physical Therapy by 1.5% during the first quarter. <em>BlackRock</em> <em>Inc</em>. now owns 578,020 shares of the company’s stock valued at $1,087,000 after purchasing an additional 8,799 shares in the last quarter. Hedge funds and other institutional investors own 91.13% of the company’s stock.",
"sentiment": 0.743,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMO",
"name": "Bank of Montreal",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 28.53084,
"sentiment_score": 0.743,
"highlights": [
{
"highlight": "<em>Bank</em> <em>of</em> <em>Montreal</em> Can lifted its holdings in ATI Physical Therapy by 45.0% during the second quarter. <em>Bank</em> <em>of</em> <em>Montreal</em> Can now owns 1,041,568 shares of the company’s stock valued at $1,854,000 after purchasing an additional 323,342 shares in the last quarter.",
"sentiment": 0.743,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ATIP",
"name": "ATI Physical Therapy, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 250.25636,
"sentiment_score": 0.348591,
"highlights": [
{
"highlight": "<em>ATI</em> <em>Physical</em> <em>Therapy</em>, <em>Inc</em>. (<em>NYSE:ATIP</em> – Get Rating) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 3,600,000 shares, a decline of 5.0% from the August 31st total of 3,790,000 shares.",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ATI</em> <em>Physical</em> <em>Therapy</em> Trading Down 3.8 %\n\n<em>NYSE:ATIP</em> opened at $1.00 on Monday. <em>ATI</em> <em>Physical</em> <em>Therapy</em> has a 52 week low of $0.85 and a 52 week high of $4.57. The firm has a 50 day moving average of $1.04 and a 200 day moving average of $1.48. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 1.79.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>ATI</em> <em>Physical</em> <em>Therapy</em> alerts:\n\n<em>ATI</em> <em>Physical</em> <em>Therapy</em> (<em>NYSE:ATIP</em> – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02).",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ATI</em> <em>Physical</em> <em>Therapy</em> had a negative net margin of 95.69% and a negative return on equity of 17.43%. As a group, sell-side analysts anticipate that <em>ATI</em> <em>Physical</em> <em>Therapy</em> will post -0.16 earnings per share for the current fiscal year.",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Institutional Inflows and Outflows\n\nWall Street Analyst Weigh In\n\nA number of hedge funds and other institutional investors have recently made changes to their positions in <em>ATIP</em>. Vanguard Group Inc. increased its stake in shares of <em>ATI</em> <em>Physical</em> <em>Therapy</em> by 124.5% in the first quarter.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Royce & Associates LP grew its position in <em>ATI</em> <em>Physical</em> <em>Therapy</em> by 9.7% during the second quarter. Royce & Associates LP now owns 1,471,800 shares of the company’s stock valued at $2,075,000 after buying an additional 130,000 shares during the period.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Bank of Montreal Can lifted its holdings in <em>ATI</em> <em>Physical</em> <em>Therapy</em> by 45.0% during the second quarter. Bank of Montreal Can now owns 1,041,568 shares of the company’s stock valued at $1,854,000 after purchasing an additional 323,342 shares in the last quarter.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "State Street Corp lifted its holdings in <em>ATI</em> <em>Physical</em> <em>Therapy</em> by 476.7% during the second quarter. State Street Corp now owns 968,355 shares of the company’s stock valued at $1,365,000 after purchasing an additional 800,445 shares in the last quarter.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ATI</em> <em>Physical</em> <em>Therapy</em> Company Profile\n\n(Get Rating)\n\n<em>ATI</em> <em>Physical</em> <em>Therapy</em>, <em>Inc</em> operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "See Also\n\nReceive News & Ratings for <em>ATI</em> <em>Physical</em> <em>Therapy</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>ATI</em> <em>Physical</em> <em>Therapy</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ATI</em> <em>Physical</em> <em>Therapy</em>, <em>Inc</em>. (<em>NYSE:ATIP</em>) Sees Large Decline in Short Interest",
"sentiment": 0.4588,
"highlighted_in": "title"
}
]
},
{
"symbol": "BLQA.DE",
"name": "BlackRock, Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Financial Services",
"match_score": 21.877735,
"sentiment_score": 0.743,
"highlights": [
{
"highlight": "Finally, <em>BlackRock</em> <em>Inc</em>. lifted its holdings in ATI Physical Therapy by 1.5% during the first quarter. <em>BlackRock</em> <em>Inc</em>. now owns 578,020 shares of the company’s stock valued at $1,087,000 after purchasing an additional 8,799 shares in the last quarter. Hedge funds and other institutional investors own 91.13% of the company’s stock.",
"sentiment": 0.743,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "cd7d758f-396b-4b01-a2a9-b1cedddc3a60",
"title": "Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Receives Average Recommendation of “Moderate Buy” from Analysts",
"description": "Read Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Receives Average Recommendation of “Moderate Buy” from Analysts at ETF Daily News",
"keywords": "Aurinia Pharmaceuticals, NASDAQ:AUPH, AUPH, Medical, Ratings, Consensus",
"snippet": "Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) have been assigned an average recommendation of “Moderate Buy” from the seven ...",
"url": "https://www.etfdailynews.com/2022/10/03/aurinia-pharmaceuticals-inc-nasdaqauph-receives-average-recommendation-of-moderate-buy-from-analysts/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/aurinia-pharmaceuticals-inc-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:30:44.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "AUPH",
"name": "Aurinia Pharmaceuticals Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 181.65758,
"sentiment_score": 0.281991,
"highlights": [
{
"highlight": "Shares of <em>Aurinia</em> <em>Pharmaceuticals</em> <em>Inc</em>. (<em>NASDAQ:AUPH</em> – Get Rating) (TSE:AUP) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "HC Wainwright dropped their price target on <em>Aurinia</em> <em>Pharmaceuticals</em> from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday, August 9th. Royal Bank of Canada dropped their price target on <em>Aurinia</em> <em>Pharmaceuticals</em> from $22.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, August 5th.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Oppenheimer decreased their target price on <em>Aurinia</em> <em>Pharmaceuticals</em> from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Monday, August 8th.\n\nGet <em>Aurinia</em> <em>Pharmaceuticals</em> alerts:\n\n<em>Aurinia</em> <em>Pharmaceuticals</em> Trading Up 0.9 %\n\nShares of <em>Aurinia</em> <em>Pharmaceuticals</em> stock opened at $7.52 on Monday.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Aurinia</em> <em>Pharmaceuticals</em> has a 12 month low of $6.28 and a 12 month high of $33.97.\n\nInstitutional Trading of <em>Aurinia</em> <em>Pharmaceuticals</em>\n\n<em>Aurinia</em> <em>Pharmaceuticals</em> ( <em>NASDAQ:AUPH</em> Get Rating ) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 4th.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Aurinia</em> <em>Pharmaceuticals</em> had a negative return on equity of 38.01% and a negative net margin of 178.32%. During the same quarter last year, the business posted ($0.37) earnings per share. Analysts predict that <em>Aurinia</em> <em>Pharmaceuticals</em> will post -0.85 EPS for the current fiscal year.",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Bellevue Group AG purchased a new position in shares of <em>Aurinia</em> <em>Pharmaceuticals</em> in the first quarter valued at $29,784,000. State Street Corp grew its position in shares of <em>Aurinia</em> <em>Pharmaceuticals</em> by 355.5% in the second quarter.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "BlackRock Inc. grew its position in shares of <em>Aurinia</em> <em>Pharmaceuticals</em> by 0.4% in the first quarter. BlackRock Inc. now owns 1,827,416 shares of the biotechnology company’s stock valued at $22,624,000 after purchasing an additional 6,677 shares in the last quarter.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Northern Trust Corp grew its position in shares of <em>Aurinia</em> <em>Pharmaceuticals</em> by 897.3% in the second quarter.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Aurinia</em> <em>Pharmaceuticals</em>\n\n(Get Rating)\n\n<em>Aurinia</em> <em>Pharmaceuticals</em> <em>Inc</em>, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "See Also\n\nReceive News & Ratings for <em>Aurinia</em> <em>Pharmaceuticals</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Aurinia</em> <em>Pharmaceuticals</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Aurinia</em> <em>Pharmaceuticals</em> <em>Inc</em>. (<em>NASDAQ:AUPH</em>) Receives Average Recommendation of “Moderate Buy” from Analysts",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "a0767e72-2d9d-40c9-a62e-c331b1bfbc41",
"title": "AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Analysts",
"description": "Read AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Analysts at ETF Daily News",
"keywords": "AstraZeneca, LON:AZN, AZN, Medical, Ratings, Consensus",
"snippet": "Shares of AstraZeneca PLC (LON:AZN – Get Rating) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are currently co...",
"url": "https://www.etfdailynews.com/2022/10/03/astrazeneca-plc-lonazn-given-consensus-recommendation-of-moderate-buy-by-analysts/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/astrazeneca-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:30:42.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 77.06339,
"sentiment_score": 0.210578,
"highlights": [
{
"highlight": "Shares of <em>AstraZeneca</em> <em>PLC</em> (LON:AZN – Get Rating) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Shore Capital restated a “buy” rating on shares of <em>AstraZeneca</em> in a research note on Monday, September 5th.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Jefferies Financial Group set a GBX 9,800 ($118.41) price objective on shares of <em>AstraZeneca</em> in a research note on Wednesday, September 14th. set a £120 ($145.00) price objective on shares of <em>AstraZeneca</em> in a research note on Monday, August 1st.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Credit Suisse Group lowered shares of <em>AstraZeneca</em> to a “neutral” rating and set a £110 ($132.91) price target on the stock. in a research note on Thursday, September 15th. Finally, Citigroup reiterated a “buy” rating on shares of <em>AstraZeneca</em> in a research note on Tuesday, July 12th.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>AstraZeneca</em> alerts:\n\n<em>AstraZeneca</em> Trading Up 0.1 %\n\nLON AZN opened at GBX 9,944 ($120.15) on Monday. The company has a debt-to-equity ratio of 87.31, a quick ratio of 0.67 and a current ratio of 0.96. The firm has a market cap of £154.08 billion and a PE ratio of -169.12.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> has a one year low of GBX 8,090.32 ($97.76) and a one year high of £115.40 ($139.44). The firm’s fifty day moving average is £106.39 and its two-hundred day moving average is £104.97.\n\n<em>AstraZeneca</em> Cuts Dividend\n\nAbout <em>AstraZeneca</em>\n\nThe business also recently disclosed a dividend, which was paid on Monday, September 12th.",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "(Get Rating)\n\n<em>AstraZeneca</em> <em>PLC</em>, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Further Reading\n\nReceive News & Ratings for <em>AstraZeneca</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>AstraZeneca</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Analysts",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "5d9fb535-193a-4c88-a9a6-5c707ac334c7",
"title": "HCA Healthcare, Inc. (NYSE:HCA) Given Consensus Recommendation of “Moderate Buy” by Brokerages",
"description": "Read HCA Healthcare, Inc. (NYSE:HCA) Given Consensus Recommendation of “Moderate Buy” by Brokerages at ETF Daily News",
"keywords": "HCA Healthcare, NYSE:HCA, HCA, Medical, 40412C10, Ratings, Consensus",
"snippet": "Shares of HCA Healthcare, Inc. (NYSE:HCA – Get Rating) have been given an average recommendation of “Moderate Buy” by the twenty-four research firms that ...",
"url": "https://www.etfdailynews.com/2022/10/03/hca-healthcare-inc-nysehca-given-consensus-recommendation-of-moderate-buy-by-brokerages/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/hca_hospitals.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:14:48.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "C",
"name": "Citigroup Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 9.444596,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "<em>Citigroup</em> reduced their target price on shares of HCA Healthcare from $254.00 to $240.00 in a research note on Tuesday, July 26th.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DB",
"name": "Deutsche Bank Aktiengesellschaft",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 26.88453,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Finally, <em>Deutsche</em> <em>Bank</em> <em>Aktiengesellschaft</em> reduced their target price on shares of HCA Healthcare from $306.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 7th.\n\nGet HCA Healthcare alerts:\n\nInsider Transactions at HCA Healthcare\n\nIn related news, major shareholder Patricia F.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TFC",
"name": "Truist Financial Corporation",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 12.556044,
"sentiment_score": 0.5719,
"highlights": [
{
"highlight": "<em>Truist</em> <em>Financial</em> boosted their price objective on shares of HCA Healthcare from $208.00 to $240.00 and gave the stock a “buy” rating in a research note on Monday, July 25th.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HCA",
"name": "HCA Healthcare, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 184.32675,
"sentiment_score": 0.438809,
"highlights": [
{
"highlight": "Shares of <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em> – Get Rating) have been given an average recommendation of “Moderate Buy” by the twenty-four research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating on the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "SVB Leerink upped their price objective on shares of <em>HCA</em> <em>Healthcare</em> from $240.00 to $259.00 and gave the company an “outperform” rating in a research report on Wednesday, August 24th. Citigroup reduced their target price on shares of <em>HCA</em> <em>Healthcare</em> from $254.00 to $240.00 in a research note on Tuesday, July 26th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of <em>HCA</em> <em>Healthcare</em> from $306.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 7th.\n\nGet <em>HCA</em> <em>Healthcare</em> alerts:\n\nInsider Transactions at <em>HCA</em> <em>Healthcare</em>\n\nIn related news, major shareholder Patricia F.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Institutional Trading of <em>HCA</em> <em>Healthcare</em>\n\n<em>HCA</em> <em>Healthcare</em> Price Performance\n\nSeveral hedge funds and other institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers boosted its holdings in <em>HCA</em> <em>Healthcare</em> by 11.7% in the 4th quarter.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Chilton Capital Management LLC bought a new stake in <em>HCA</em> <em>Healthcare</em> in the 4th quarter valued at about $49,000. MML Investors Services LLC boosted its holdings in <em>HCA</em> <em>Healthcare</em> by 9.6% in the 4th quarter.",
"sentiment": 0.8455,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Mirova lifted its holdings in shares of <em>HCA</em> <em>Healthcare</em> by 397.2% during the 4th quarter. Mirova now owns 16,128 shares of the company’s stock worth $4,143,000 after acquiring an additional 12,884 shares during the period. Institutional investors own 65.75% of the company’s stock.\n\n<em>NYSE</em> <em>HCA</em> opened at $183.79 on Monday.",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em> has a 12-month low of $164.47 and a 12-month high of $279.02.\n\n<em>HCA</em> <em>Healthcare</em> (<em>NYSE:HCA</em> – Get Rating) last issued its quarterly earnings data on Friday, July 22nd. The company reported $4.21 earnings per share for the quarter, topping analysts’ consensus estimates of $3.67 by $0.54.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "As a group, equities analysts predict that <em>HCA</em> <em>Healthcare</em> will post 17.04 earnings per share for the current fiscal year.\n\n<em>HCA</em> <em>Healthcare</em> Announces Dividend\n\nThe firm also recently disclosed a quarterly dividend, which was paid on Friday, September 30th. Shareholders of record on Friday, September 16th were paid a $0.56 dividend.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em> Company Profile\n\n(Get Rating)\n\n<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>, through its subsidiaries, provides health care services company in the United States.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Recommended Stories\n\nReceive News & Ratings for <em>HCA</em> <em>Healthcare</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>HCA</em> <em>Healthcare</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.7034,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>) Given Consensus Recommendation of “Moderate Buy” by Brokerages",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "DBK.DE",
"name": "Deutsche Bank Aktiengesellschaft",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Financial Services",
"match_score": 23.156128,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Finally, <em>Deutsche</em> <em>Bank</em> <em>Aktiengesellschaft</em> reduced their target price on shares of HCA Healthcare from $306.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 7th.\n\nGet HCA Healthcare alerts:\n\nInsider Transactions at HCA Healthcare\n\nIn related news, major shareholder Patricia F.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "bdeaf451-4cad-4553-b193-cb1abbe0a366",
"title": "Oxford's Eden Research reports half-year revenue of £1.04m",
"description": "Eden Research PLC, an Oxford-based sustainable biopesticide company which is developing plastic-free technology for use in crop protection...",
"keywords": "",
"snippet": "Eden Research PLC, an Oxford-based sustainable biopesticide company which is developing plastic-free technology for use in crop protection, animal health and co...",
"url": "https://businessmag.co.uk/corporate-finance/oxfords-eden-research-reports-half-year-revenue-of-1-04m/",
"image_url": "https://businessmag.co.uk/wp-content/uploads/2022/09/Eden-Research-FRFI.jpg",
"language": "en",
"published_at": "2022-10-03T06:26:41.000000Z",
"source": "businessmag.co.uk",
"relevance_score": null,
"entities": [
{
"symbol": "MLAHC.PA",
"name": "@Health SA",
"exchange": "EPA",
"exchange_long": "Euronext Paris",
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.571369,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Eden Research PLC, an Oxford-based sustainable biopesticide company which is developing plastic-free technology for use in crop protection, animal <em>health</em> and consumer products, has reported a revenue of £1.04 million for the six months ended 30 June 2022.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "996eda67-30f7-46f5-8726-9782f984ac0d",
"title": "FY2023 EPS Estimates for Zoetis Inc. (NYSE:ZTS) Boosted by Cantor Fitzgerald",
"description": "Read FY2023 EPS Estimates for Zoetis Inc. (NYSE:ZTS) Boosted by Cantor Fitzgerald at ETF Daily News",
"keywords": "Zoetis, NYSE:ZTS, ZTS, Medical, 98978V10, Earnings Estimates, Cantor Fitzgerald",
"snippet": "Zoetis Inc. (NYSE:ZTS – Get Rating) – Investment analysts at Cantor Fitzgerald raised their FY2023 earnings per share estimates for shares of Zoetis in a re...",
"url": "https://www.etfdailynews.com/2022/10/03/fy2023-eps-estimates-for-zoetis-inc-nysezts-boosted-by-cantor-fitzgerald/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/zoetis-inc-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:50.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZTS",
"name": "Zoetis Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 133.41217,
"sentiment_score": 0.320855,
"highlights": [
{
"highlight": "<em>Zoetis</em> <em>Inc</em>. (<em>NYSE:ZTS</em> – Get Rating) – Investment analysts at Cantor Fitzgerald raised their FY2023 earnings per share estimates for shares of <em>Zoetis</em> in a research note issued to investors on Friday, September 30th. Cantor Fitzgerald analyst L.",
"sentiment": 0.7983,
"highlighted_in": "main_text"
},
{
"highlight": "The consensus estimate for <em>Zoetis</em>’ current full-year earnings is $4.99 per share.\n\nGet <em>Zoetis</em> alerts:\n\n<em>Zoetis</em> (<em>NYSE:ZTS</em> – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.02).",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Zoetis</em> had a return on equity of 49.03% and a net margin of 26.14%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $1.19 EPS.\n\n<em>Zoetis</em> Trading Down 1.8 %\n\nA number of other analysts have also recently commented on ZTS.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "StockNews.com cut <em>Zoetis</em> from a “strong-buy” rating to a “buy” rating in a research report on Thursday. William Blair reiterated an “outperform” rating on shares of <em>Zoetis</em> in a research report on Friday, August 5th. Finally, Piper Sandler assumed coverage on <em>Zoetis</em> in a research report on Monday, July 11th.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Based on data from MarketBeat.com, <em>Zoetis</em> currently has an average rating of “Moderate Buy” and a consensus price target of $224.00.\n\n<em>NYSE:ZTS</em> opened at $148.29 on Monday. The company has a market capitalization of $69.42 billion, a PE ratio of 33.63, a price-to-earnings-growth ratio of 2.64 and a beta of 0.77.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Zoetis</em> has a 52-week low of $147.77 and a 52-week high of $249.27. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 1.14.\n\nHedge Funds Weigh In On <em>Zoetis</em>\n\nSeveral hedge funds and other institutional investors have recently modified their holdings of ZTS.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Worth Asset Management LLC acquired a new position in <em>Zoetis</em> during the 1st quarter worth approximately $26,000. Financial Management Professionals Inc. lifted its position in <em>Zoetis</em> by 117.4% during the 1st quarter.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Buying and Selling at <em>Zoetis</em>\n\nIn other <em>Zoetis</em> news, EVP Roxanne Lagano sold 2,167 shares of <em>Zoetis</em> stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Zoetis</em>\n\n(Get Rating)\n\n<em>Zoetis</em> <em>Inc</em> discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Articles\n\nReceive News & Ratings for <em>Zoetis</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Zoetis</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "FY2023 EPS Estimates for <em>Zoetis</em> <em>Inc</em>. (<em>NYSE:ZTS</em>) Boosted by Cantor Fitzgerald",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZOE.DE",
"name": "Zoetis Inc.",
"exchange": "XETRA",
"exchange_long": "Deutsche Börse Xetra",
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 92.78931,
"sentiment_score": 0.320855,
"highlights": [
{
"highlight": "<em>Zoetis</em> <em>Inc</em>. (NYSE:ZTS – Get Rating) – Investment analysts at Cantor Fitzgerald raised their FY2023 earnings per share estimates for shares of <em>Zoetis</em> in a research note issued to investors on Friday, September 30th. Cantor Fitzgerald analyst L.",
"sentiment": 0.7983,
"highlighted_in": "main_text"
},
{
"highlight": "The consensus estimate for <em>Zoetis</em>’ current full-year earnings is $4.99 per share.\n\nGet <em>Zoetis</em> alerts:\n\n<em>Zoetis</em> (NYSE:ZTS – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.02).",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Zoetis</em> had a return on equity of 49.03% and a net margin of 26.14%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $1.19 EPS.\n\n<em>Zoetis</em> Trading Down 1.8 %\n\nA number of other analysts have also recently commented on ZTS.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Stifel Nicolaus dropped their price objective on <em>Zoetis</em> from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. The Goldman Sachs Group dropped their price objective on <em>Zoetis</em> from $208.00 to $202.00 and set a “buy” rating for the company in a research report on Thursday, July 21st.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "StockNews.com cut <em>Zoetis</em> from a “strong-buy” rating to a “buy” rating in a research report on Thursday. William Blair reiterated an “outperform” rating on shares of <em>Zoetis</em> in a research report on Friday, August 5th. Finally, Piper Sandler assumed coverage on <em>Zoetis</em> in a research report on Monday, July 11th.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Zoetis</em> has a 52-week low of $147.77 and a 52-week high of $249.27. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 1.14.\n\nHedge Funds Weigh In On <em>Zoetis</em>\n\nSeveral hedge funds and other institutional investors have recently modified their holdings of ZTS.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Worth Asset Management LLC acquired a new position in <em>Zoetis</em> during the 1st quarter worth approximately $26,000. Financial Management Professionals Inc. lifted its position in <em>Zoetis</em> by 117.4% during the 1st quarter.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Buying and Selling at <em>Zoetis</em>\n\nIn other <em>Zoetis</em> news, EVP Roxanne Lagano sold 2,167 shares of <em>Zoetis</em> stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Zoetis</em>\n\n(Get Rating)\n\n<em>Zoetis</em> <em>Inc</em> discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Articles\n\nReceive News & Ratings for <em>Zoetis</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Zoetis</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "FY2023 EPS Estimates for <em>Zoetis</em> <em>Inc</em>. (NYSE:ZTS) Boosted by Cantor Fitzgerald",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "a9cff25e-7a63-4500-bc41-3db5de579ed6",
"title": "Cantor Fitzgerald Weighs in on Cerevel Therapeutics Holdings, Inc.’s FY2022 Earnings (NASDAQ:CERE)",
"description": "Read Cantor Fitzgerald Weighs in on Cerevel Therapeutics Holdings, Inc.’s FY2022 Earnings (NASDAQ:CERE) at ETF Daily News",
"keywords": "Cerevel Therapeutics, NASDAQ:CERE, CERE, Medical, 15677310, Earnings Estimates, Cantor Fitzgerald",
"snippet": "Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for...",
"url": "https://www.etfdailynews.com/2022/10/03/cantor-fitzgerald-weighs-in-on-cerevel-therapeutics-holdings-inc-s-fy2022-earnings-nasdaqcere/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/ceres-inc-logo.jpg?v2&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T05:30:44.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "WFC",
"name": "Wells Fargo & Company",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 20.959572,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Wells</em> <em>Fargo</em> & <em>Company</em> began coverage on Cerevel Therapeutics in a research report on Monday, September 26th. They set an “overweight” rating and a $38.00 price target for the company.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CERE",
"name": "Cerevel Therapeutics Holdings, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 220.44705,
"sentiment_score": 0.1684,
"highlights": [
{
"highlight": "<em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>. (<em>NASDAQ:CERE</em> – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for Cerevel Therapeutics in a research note issued to investors on Thursday, September 29th. Cantor Fitzgerald analyst C.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Cerevel Therapeutics Stock Up 1.4 %\n\n<em>NASDAQ:CERE</em> opened at $28.26 on Monday. The company has a market cap of $4.20 billion, a P/E ratio of -14.87 and a beta of 1.96. The firm’s 50 day moving average is $30.33 and its two-hundred day moving average is $29.39.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Cerevel Therapeutics (<em>NASDAQ:CERE</em> – Get Rating) last issued its quarterly earnings results on Monday, August 1st. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.14). During the same quarter in the prior year, the business posted ($0.42) earnings per share.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About Cerevel Therapeutics\n\n(Get Rating)\n\n<em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald Weighs in on <em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>.’s FY2022 Earnings (<em>NASDAQ:CERE</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "CEREW",
"name": "Cerevel Therapeutics Holdings, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 179.82526,
"sentiment_score": 0.182,
"highlights": [
{
"highlight": "<em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>. (NASDAQ:CERE – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for Cerevel Therapeutics in a research note issued to investors on Thursday, September 29th. Cantor Fitzgerald analyst C.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About Cerevel Therapeutics\n\n(Get Rating)\n\n<em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald Weighs in on <em>Cerevel</em> <em>Therapeutics</em> <em>Holdings</em>, <em>Inc</em>.’s FY2022 Earnings (NASDAQ:CERE)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "30ef45c0-9270-44a9-9304-bcf5109f0595",
"title": "Second Sight Medical Products (NASDAQ:EYES) Now Covered by StockNews.com",
"description": "Read Second Sight Medical Products (NASDAQ:EYES) Now Covered by StockNews.com at ETF Daily News",
"keywords": "Second Sight Medical Products, NASDAQ:EYES, EYES, Medical, Initiated Coverage, StockNews.com",
"snippet": "Stock analysts at StockNews.com began coverage on shares of Second Sight Medical Products (NASDAQ:EYES – Get Rating) in a report issued on Monday. The firm se...",
"url": "https://www.etfdailynews.com/2022/10/03/second-sight-medical-products-nasdaqeyes-now-covered-by-stocknews-com/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/second-sight-medical-products-inc-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:49.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "EYES",
"name": "Second Sight Medical Products, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 191.51447,
"sentiment_score": 0.413856,
"highlights": [
{
"highlight": "Stock analysts at StockNews.com began coverage on shares of <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> (<em>NASDAQ:EYES</em> – Get Rating) in a report issued on Monday. The firm set a “sell” rating on the medical device company’s stock.\n\n<em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> Stock Performance\n\n<em>NASDAQ</em> <em>EYES</em> opened at $4.14 on Monday.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> has a one year low of $3.42 and a one year high of $12.72. The stock’s 50 day simple moving average is $5.71 and its 200 day simple moving average is $5.21.\n\nGet <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> alerts:\n\nInstitutional Inflows and Outflows\n\nLarge investors have recently bought and sold shares of the company.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Jane Street Group LLC lifted its holdings in <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> by 111.8% during the 2nd quarter. Jane Street Group LLC now owns 21,601 shares of the medical device company’s stock worth $44,000 after buying an additional 11,403 shares in the last quarter.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Virtu Financial LLC lifted its stake in shares of <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> by 130.6% in the 2nd quarter. Virtu Financial LLC now owns 31,258 shares of the medical device company’s stock valued at $63,000 after purchasing an additional 17,703 shares during the period.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "Millennium Management LLC acquired a new stake in <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> during the 2nd quarter worth $207,000. Renaissance Technologies LLC acquired a new stake in <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> during the 1st quarter worth $249,000.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Vanguard Group Inc. raised its stake in <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company’s stock worth $1,747,000 after buying an additional 17,164 shares during the period.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> Company Profile\n\n<em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em>, <em>Inc</em> develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "See Also\n\nReceive News & Ratings for <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Second</em> <em>Sight</em> <em>Medical</em> <em>Products</em> (<em>NASDAQ:EYES</em>) Now Covered by StockNews.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "d852c66b-6daf-4224-be93-a237fc06e1c3",
"title": "Heat Biologics (NASDAQ:HTBX) Now Covered by Analysts at StockNews.com",
"description": "Read Heat Biologics (NASDAQ:HTBX) Now Covered by Analysts at StockNews.com at ETF Daily News",
"keywords": "Heat Biologics, NASDAQ:HTBX, HTBX, Medical, Initiated Coverage, StockNews.com",
"snippet": "StockNews.com began coverage on shares of Heat Biologics (NASDAQ:HTBX – Get Rating) in a note issued to investors on Monday. The brokerage set a “sell” ra...",
"url": "https://www.etfdailynews.com/2022/10/03/heat-biologics-nasdaqhtbx-now-covered-by-analysts-at-stocknews-com/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/heat-biologics-inc-logo.png?v=20220603101024&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:48.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "HTBX",
"name": "Heat Biologics, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 137.56985,
"sentiment_score": 0.3257,
"highlights": [
{
"highlight": "StockNews.com began coverage on shares of <em>Heat</em> <em>Biologics</em> (<em>NASDAQ:HTBX</em> – Get Rating) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.\n\n<em>Heat</em> <em>Biologics</em> Stock Up 0.4 %\n\nHTBX opened at $2.38 on Monday. <em>Heat</em> <em>Biologics</em> has a fifty-two week low of $2.07 and a fifty-two week high of $10.85.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>Heat</em> <em>Biologics</em> alerts:\n\nInstitutional Investors Weigh In On <em>Heat</em> <em>Biologics</em>\n\nA hedge fund recently raised its stake in <em>Heat</em> <em>Biologics</em> stock. Jane Street Group LLC boosted its position in <em>Heat</em> <em>Biologics</em>, <em>Inc</em>. (<em>NASDAQ:HTBX</em> – Get Rating) by 341.4% in the first quarter, according to its most recent filing with the SEC.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Jane Street Group LLC owned about 0.07% of <em>Heat</em> <em>Biologics</em> worth $54,000 as of its most recent SEC filing.\n\nAbout <em>Heat</em> <em>Biologics</em>\n\n<em>Heat</em> <em>Biologics</em>, <em>Inc</em>, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Further Reading\n\nReceive News & Ratings for <em>Heat</em> <em>Biologics</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Heat</em> <em>Biologics</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Heat</em> <em>Biologics</em> (<em>NASDAQ:HTBX</em>) Now Covered by Analysts at StockNews.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "d1e3d118-d776-45d1-8293-132b1ff532af",
"title": "StockNews.com Begins Coverage on ContraFect (NASDAQ:CFRX)",
"description": "Read StockNews.com Begins Coverage on ContraFect (NASDAQ:CFRX) at ETF Daily News",
"keywords": "ContraFect, NASDAQ:CFRX, CFRX, Medical, Initiated Coverage, StockNews.com",
"snippet": "Analysts at StockNews.com initiated coverage on shares of ContraFect (NASDAQ:CFRX – Get Rating) in a note issued to investors on Monday. The brokerage set a ?...",
"url": "https://www.etfdailynews.com/2022/10/03/stocknews-com-begins-coverage-on-contrafect-nasdaqcfrx-2/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/contrafect-corp-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:49.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "CFRX",
"name": "ContraFect Corporation",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 119.977295,
"sentiment_score": 0.351564,
"highlights": [
{
"highlight": "Analysts at StockNews.com initiated coverage on shares of <em>ContraFect</em> (<em>NASDAQ:CFRX</em> – Get Rating) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.\n\nSeveral other equities analysts have also commented on the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "SVB Leerink lowered <em>ContraFect</em> from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $9.00 to $1.00 in a research note on Thursday, July 14th. Maxim Group lowered <em>ContraFect</em> from a “buy” rating to a “hold” rating in a research note on Thursday, July 14th.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald reiterated a “neutral” rating and issued a $1.00 target price (down from $15.00) on shares of <em>ContraFect</em> in a research note on Thursday, July 14th. Finally, WBB Securities upgraded <em>ContraFect</em> to a “strong-buy” rating and set a $7.00 target price for the company in a research note on Wednesday, June 8th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>ContraFect</em> alerts:\n\n<em>ContraFect</em> Stock Down 6.5 %\n\nShares of <em>NASDAQ:CFRX</em> opened at $0.17 on Monday. <em>ContraFect</em> has a 52-week low of $0.16 and a 52-week high of $4.54. The stock’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $2.21.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Institutional Investors Weigh In On <em>ContraFect</em>\n\n<em>ContraFect</em> ( <em>NASDAQ:CFRX</em> Get Rating ) last issued its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On average, sell-side analysts anticipate that <em>ContraFect</em> will post -1.34 earnings per share for the current year.\n\nInstitutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of <em>ContraFect</em> by 0.7% in the first quarter.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "State Street Corp boosted its position in shares of <em>ContraFect</em> by 33.5% in the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares during the period.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Envestnet Asset Management Inc. purchased a new stake in shares of <em>ContraFect</em> in the first quarter worth about $41,000. Hedge funds and other institutional investors own 63.80% of the company’s stock.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ContraFect</em> Company Profile\n\n(Get Rating)\n\n<em>ContraFect</em> <em>Corporation</em>, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for <em>ContraFect</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>ContraFect</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "StockNews.com Begins Coverage on <em>ContraFect</em> (<em>NASDAQ:CFRX</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "0b5e51ad-3657-4973-bd81-2021cc7f6491",
"title": "StockNews.com Begins Coverage on Quotient (NASDAQ:QTNT)",
"description": "Read StockNews.com Begins Coverage on Quotient (NASDAQ:QTNT) at ETF Daily News",
"keywords": "Quotient, NASDAQ:QTNT, QTNT, Medical, Initiated Coverage, StockNews.com",
"snippet": "StockNews.com assumed coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research note issued to investors on Monday. The brokerage set a “hold?...",
"url": "https://www.etfdailynews.com/2022/10/03/stocknews-com-begins-coverage-on-quotient-nasdaqqtnt/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/quotient-ltd-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:45.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "QTNT",
"name": "Quotient Limited",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 65.27773,
"sentiment_score": 0.105375,
"highlights": [
{
"highlight": "StockNews.com assumed coverage on shares of Quotient (<em>NASDAQ:QTNT</em> – Get Rating) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the stock.\n\nQTNT has been the subject of several other reports.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Activity\n\nQuotient ( <em>NASDAQ:QTNT</em> Get Rating ) last posted its earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.40 million.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Quotient Company Profile\n\n(Get Rating)\n\n<em>Quotient</em> <em>Limited</em>, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "StockNews.com Begins Coverage on Quotient (<em>NASDAQ:QTNT</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "3a8209e1-e04d-40aa-9427-4beae8fe9ca0",
"title": "Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com",
"description": "Read Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com at ETF Daily News",
"keywords": "Enzo Biochem, NYSE:ENZ, ENZ, Medical, Initiated Coverage, StockNews.com",
"snippet": "Analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ – Get Rating) in a research report issued on Monday. The brokerage set a “hol...",
"url": "https://www.etfdailynews.com/2022/10/03/enzo-biochem-nyseenz-coverage-initiated-at-stocknews-com/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/enzo-biochem-inc-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-03T06:18:43.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "ENZ",
"name": "Enzo Biochem, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 176.97287,
"sentiment_score": 0.4131,
"highlights": [
{
"highlight": "Analysts at StockNews.com assumed coverage on shares of <em>Enzo</em> <em>Biochem</em> (<em>NYSE:ENZ</em> – Get Rating) in a research report issued on Monday. The brokerage set a “hold” rating on the medical research company’s stock.\n\n<em>Enzo</em> <em>Biochem</em> Stock Performance\n\n<em>NYSE</em> <em>ENZ</em> opened at $2.23 on Monday.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Enzo</em> <em>Biochem</em> has a 1-year low of $1.98 and a 1-year high of $4.15.\n\nGet <em>Enzo</em> <em>Biochem</em> alerts:\n\nInsider Transactions at <em>Enzo</em> <em>Biochem</em>\n\nIn other news, Director Bradley Louis Radoff acquired 120,000 shares of the company’s stock in a transaction dated Tuesday, July 5th.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Institutional Trading of <em>Enzo</em> <em>Biochem</em>\n\nAbout <em>Enzo</em> <em>Biochem</em>\n\nHedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. acquired a new stake in shares of <em>Enzo</em> <em>Biochem</em> in the second quarter valued at approximately $38,000. Shufro Rose & Co.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "LLC acquired a new stake in shares of <em>Enzo</em> <em>Biochem</em> in the first quarter valued at approximately $39,000. Assenagon Asset Management S.A. acquired a new stake in shares of <em>Enzo</em> <em>Biochem</em> in the second quarter valued at approximately $41,000.",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Virtu Financial LLC acquired a new stake in shares of <em>Enzo</em> <em>Biochem</em> in the second quarter valued at approximately $62,000. Finally, SNS Financial Group LLC acquired a new stake in shares of <em>Enzo</em> <em>Biochem</em> in the first quarter valued at approximately $181,000. Institutional investors and hedge funds own 43.29% of the company’s stock.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "(Get Rating)\n\n<em>Enzo</em> <em>Biochem</em>, <em>Inc</em>, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "See Also\n\nReceive News & Ratings for <em>Enzo</em> <em>Biochem</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Enzo</em> <em>Biochem</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Enzo</em> <em>Biochem</em> (<em>NYSE:ENZ</em>) Coverage Initiated at StockNews.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "PUK",
"name": "Prudential plc",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 14.451494,
"sentiment_score": 0.8481,
"highlights": [
{
"highlight": "<em>Prudential</em> Financial Inc. acquired a new stake in shares of Enzo Biochem in the second quarter valued at approximately $38,000. Shufro Rose & Co. LLC acquired a new stake in shares of Enzo Biochem in the first quarter valued at approximately $39,000.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PUK-P",
"name": "Prudential plc",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 14.451497,
"sentiment_score": 0.8481,
"highlights": [
{
"highlight": "<em>Prudential</em> Financial Inc. acquired a new stake in shares of Enzo Biochem in the second quarter valued at approximately $38,000. Shufro Rose & Co. LLC acquired a new stake in shares of Enzo Biochem in the first quarter valued at approximately $39,000.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PRU",
"name": "Prudential Financial, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 33.46585,
"sentiment_score": 0.8481,
"highlights": [
{
"highlight": "<em>Prudential</em> <em>Financial</em> <em>Inc</em>. acquired a new stake in shares of Enzo Biochem in the second quarter valued at approximately $38,000. Shufro Rose & Co. LLC acquired a new stake in shares of Enzo Biochem in the first quarter valued at approximately $39,000.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PUK-WI",
"name": "Prudential plc",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 14.450888,
"sentiment_score": 0.8481,
"highlights": [
{
"highlight": "<em>Prudential</em> Financial Inc. acquired a new stake in shares of Enzo Biochem in the second quarter valued at approximately $38,000. Shufro Rose & Co. LLC acquired a new stake in shares of Enzo Biochem in the first quarter valued at approximately $39,000.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 784,
"sentiment_avg": 0.3005380509142845
}
]
}
Other details
Entity count
- 12,299